Browsing College of Pharmacy by Subject "newly diagnosed multiple myeloma (NDMM)"
Now showing items 1-1 of 1
-
COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS DARATUMUMAB VERSUS INTRAVENOUS DARATUMUMAB IN NEWLY DIAGNOSED MULTIPLE MYELOMA
(2024 , Master Thesis)Background: Both subcutaneous (SC) and intravenous (IV) formulations of Daratumumab (Dara) are used, in combination with lenalidomide, bortezomib, and dexamethasone (VRd), for treating newly diagnosed multiple myeloma ...